These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
442 related articles for article (PubMed ID: 28912090)
1. Immuno-oncology and Its Opportunities for Interventional Radiologists: Immune Checkpoint Inhibition and Potential Synergies with Interventional Oncology Procedures. Hickey RM; Kulik LM; Nimeiri H; Kalyan A; Kircher S; Desai K; Riaz A; Lewandowski RJ; Salem R J Vasc Interv Radiol; 2017 Nov; 28(11):1487-1494. PubMed ID: 28912090 [TBL] [Abstract][Full Text] [Related]
2. Reply to: "Re: Immuno-oncology and Its Opportunities for Interventional Radiologists: Immune Checkpoint Inhibition and Potential Synergies with Interventional Oncology Procedures". Hickey RM J Vasc Interv Radiol; 2018 Apr; 29(4):587. PubMed ID: 29579466 [No Abstract] [Full Text] [Related]
3. Cancer Immunotherapy: A Simple Guide for Interventional Radiologists of New Therapeutic Approaches. Digklia A; Duran R; Homicsko K; Kandalaft LE; Hocquelet A; Orcurto A; Coukos G; Denys A Cardiovasc Intervent Radiol; 2019 Sep; 42(9):1221-1229. PubMed ID: 30209564 [TBL] [Abstract][Full Text] [Related]
4. Immunotherapy and the Interventional Oncologist: Challenges and Opportunities-A Society of Interventional Oncology White Paper. Erinjeri JP; Fine GC; Adema GJ; Ahmed M; Chapiro J; den Brok M; Duran R; Hunt SJ; Johnson DT; Ricke J; Sze DY; Toskich BB; Wood BJ; Woodrum D; Goldberg SN Radiology; 2019 Jul; 292(1):25-34. PubMed ID: 31012818 [TBL] [Abstract][Full Text] [Related]
5. Re: Immuno-oncology and Its Opportunities for Interventional Radiologists: Immune Checkpoint Inhibition and Potential Synergies with Interventional Oncology Procedures. Huang X; Tsauo J; Zhao H; Li X J Vasc Interv Radiol; 2018 Apr; 29(4):586. PubMed ID: 29579465 [No Abstract] [Full Text] [Related]
6. PET Assessment of Immune Effects from Interventional Oncology Procedures. Hunt SJ; Seraj SM; Alavi A PET Clin; 2019 Oct; 14(4):477-485. PubMed ID: 31472745 [TBL] [Abstract][Full Text] [Related]
10. Update on New Therapies With Immune Checkpoint Inhibitors. Peterson JJ; Steele-Moses SK Clin J Oncol Nurs; 2016 Aug; 20(4):405-10. PubMed ID: 27441513 [TBL] [Abstract][Full Text] [Related]
11. Combining antibody-drug conjugates and immune-mediated cancer therapy: What to expect? Gerber HP; Sapra P; Loganzo F; May C Biochem Pharmacol; 2016 Feb; 102():1-6. PubMed ID: 26686577 [TBL] [Abstract][Full Text] [Related]
12. Trends and challenges in immuno-oncology trials. Kiernan B Drugs Today (Barc); 2016 Jul; 52(7):387-93. PubMed ID: 27540597 [TBL] [Abstract][Full Text] [Related]
13. The evolution of interventional oncology in the 21st century. Helmberger T Br J Radiol; 2020 Sep; 93(1113):20200112. PubMed ID: 32706978 [TBL] [Abstract][Full Text] [Related]
15. The emerging role of epigenetic therapeutics in immuno-oncology. Topper MJ; Vaz M; Marrone KA; Brahmer JR; Baylin SB Nat Rev Clin Oncol; 2020 Feb; 17(2):75-90. PubMed ID: 31548600 [TBL] [Abstract][Full Text] [Related]
16. Immuno-oncology combinations: a review of clinical experience and future prospects. Antonia SJ; Larkin J; Ascierto PA Clin Cancer Res; 2014 Dec; 20(24):6258-68. PubMed ID: 25341541 [TBL] [Abstract][Full Text] [Related]
17. Developing and validating model systems for immuno-oncology. McCarthy CE; Zahir N; Eljanne M; Sharon E; Voest EE; Palucka K Cancer Cell; 2021 Aug; 39(8):1018-1022. PubMed ID: 34115988 [TBL] [Abstract][Full Text] [Related]
18. The interplay of immunotherapy and chemotherapy: harnessing potential synergies. Emens LA; Middleton G Cancer Immunol Res; 2015 May; 3(5):436-43. PubMed ID: 25941355 [TBL] [Abstract][Full Text] [Related]
19. Mathematical Modeling of Cancer Immunotherapy and Its Synergy with Radiotherapy. Serre R; Benzekry S; Padovani L; Meille C; André N; Ciccolini J; Barlesi F; Muracciole X; Barbolosi D Cancer Res; 2016 Sep; 76(17):4931-40. PubMed ID: 27302167 [TBL] [Abstract][Full Text] [Related]